It’s good to talk about our 𝘄𝗵𝘆 sometimes.
That’s why we appreciate Emma Ter-Azaryan’s interview so much. Not just for her insightful questions, but for giving us an opportunity to publicly reflect on 𝘄𝗵𝗮𝘁 𝗢𝗻𝗰𝗼𝘀𝗰𝗼𝗽𝗲-𝗔𝗜 𝗺𝗲𝗮𝗻𝘀 𝘁𝗼 𝘂𝘀.
In this interview with OncoDaily, Oncoscope-AI Founder & CEO Anna Forsythe shares what drives her personally, an example of an oncologist using the tool and the impact it had, and the frustration of seeing people we love treated with chemotherapy because their doctors weren’t aware of updates in the guidelines and the research behind them.
You can watch the full interview “Could Oncoscope-AI Save Clinicians Hours – and Spare Patients Side Effects?” here:
From OncoDaily:
In this episode of OncoDaily TV, host Emma Ter-Azaryan speaks with Anna Forsythe, CEO & Founder of Oncoscope-AI, to unpack how clinicians can cut through oncology’s data overload—FDA labels, guidelines, congress abstracts, and papers—and get to the right evidence in just a few clicks.
What you’ll learn:
✅ What OncoScope AI is (in simple terms): a clinician-friendly “Expedia for evidence” that pulls from major medical databases, guidelines, regulatory updates, and congress outputs—cross-linked in one place.
✅ Essential vs. Edge: two workflows—patient-first decision support vs. deep-dive topic exploration (e.g., ADCs in lung cancer, mutation-specific updates).
✅ Power features: clickable disease maps, filter by congress (ASCO, World Lung, etc.), tumor-board prep, and one-click prior-auth reports with citations.
✅ Real-world impact: how a brand-new FDA approval surfaced that week and helped a patient access a better-tolerated therapy sooner.”
